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Potential role of platelet activating factor in acute renal failure. (Kf), and (c) tubular necrosis with the subsequent tubu-
The clinical condition of acute renal failure (ARF) can be lar obstruction and fluid backleak [1]. Several research
caused by a diverse number of renal injuries, but it is generally teams have studied the active renal vasoconstriction as-characterized by a sharp reduction in the glomerular filtration
sociated with renal failure, although a fully satisfactoryrate (GFR). A lipid mediator, platelet activating factor (PAF),
explanation has not yet been found. One of the mostmay be one of the entities responsible for causing the hemody-
namic changes in the ARF kidney because it can act as a vaso- attractive research fields is the search for a factor(s)
dilator or vasoconstrictor, depending upon its concentration. locally released into the kidney that could be responsible
This review examines the action and mechanisms of PAF in for the alterations observed.experimental animal models of ischemia and nephrotoxicity, as
Acetylated alkyl phosphoglycerides constitute a newwell as renal failure associated with extrarenal diseases. While
class of lipid mediators with a wide spectrum of biologicalfurther research is necessary before extrapolating our current
knowledge of PAF into the prevention of renal failure or thera- activities. The first mediator of this class identified was a
peutic intervention using PAF antagonists in human ARF, there product released from antigen-activated, IgE-sensitized
is reasonable evidence to support its role as a mediator of the
rabbit basophils with a potent effect in aggregating anddecrease in GFR characteristic of ARF.
degranulating rabbit platelets [2]. Its name, “platelet-
activating factor” (PAF), was derived from this activity.
Acute renal failure (ARF) is a clinical entity character- The chemical structure of PAF is 1-O-alkyl-2-acetyl-sn-
ized by a sharp reduction in the glomerular filtration rate glyceryl phosphocholine [3]. Because of its structural
(GFR). ARF can result from a variety of renal injuries, definition, PAF has been also termed PAF-acether or
such as intoxication by heavy metals, organic solvents, AGEPC [2]. It has been demonstrated that PAF can be
and drugs; renal ischemia after major vascular surgery; released not only by basophils but also by several other
severe bleeding; or obstetric surgery. ARF can also result cell types and organs, including the kidney. PAF has a
from immunological glomerular injury, although this ex- wide spectrum of diverse and potent biological activities
tremely important cause of renal failure is beyond of the that have been recently reviewed in several articles [4–6].
scope of this review. The physiopathology of each type of Its effects on renal function make it an appropriate candi-
renal injury has been extensively studied by developing date as a mediator of the reduction if GFR and RBF
experimental models that mimic the circumstances of associated with renal failure of different etiologies.
the clinical condition. These models have differences in This article reviews the role of PAF in the genesis and
both the time sequence of renal events as well as the maintenance of ARF.
relative importance of each event. In all of the experi-
mental models developed thus far, there are several pro-
PLATELET-ACTIVATING FACTORcesses that seem to make a major contribution to the
AND THE KIDNEYreduction in GFR characteristic of ARF. Among them,
the most important are (a) a reduction in renal blood flow Renal effects of platelet-activating
(RBF) secondary to increased renal vascular resistance factor administration
(RVR), (b) a decrease in the ultrafiltration coefficient When injected into a systemic vein, PAF induces a
decrease in RBF, GFR, and urinary flow. These effects
are secondary to a marked decrease in arterial pressureKey words: glomerular filtration rate, renal injury, PAF, acetylated alkyl
phosphoglycerides, hemodynamics. [7–11]. PAF-induced hypotension has been found to be
associated with plasma extravasation into the interstitialReceived for publication April 21, 1998
compartment [7], as well as with a fall in cardiac outputand in revised form July 2, 1998
Accepted for publication July 6, 1998 caused by the direct effect of PAF on the coronary arter-
ies [8, 10]. Infusion of PAF directly into the renal artery 1999 by the International Society of Nephrology
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in dogs and rats results in a dose-dependent decrease in represented in Figure 1. A major substrate for PAF syn-
thesis is the phospholipid 1-O-alkyl-2-acyl glycerophos-GFR, RBF, and urine flow or sodium excretion, with
phocholine (alkylacylglycerophosphocholine), which givesno significant changes in systemic hemodynamics. Thus,
rise to 1-O-alkyl-glycerophosphocholine, called lyso-Santos et al infused PAF continuously in the renal artery
PAF, through the action of membrane phospholipaseof dogs to achieve renal arterial blood concentrations
A2. Lyso-PAF can be the substrate of either a CoA-ranging between 1028 and 1025 m, and they observed a
dependent acyl transferase, giving rise again to the phos-dose-dependent decrease in RBF and GFR [12]. Badr
pholipid 1-O-alkyl-2-acyl glycerophosphocholine, or aet al infused PAF into the renal artery of anesthetized
specific CoA-dependent acetyl transferase, giving riserats at doses between 12.5 and 50 ng · kg21 · min21, and
to the active molecule 1-O-alkyl-2-acetyl-sn-glycero-3-they observed a dose-dependent reduction of RBF and
phosphocholine (PAF). PAF can be metabolized to lyso-
GFR [13]. Similar results were also obtained by Yoo,
PAF by an acetyl hydrolase [21]. An alternative metabolic
Schlondorf and Neugarten in rats [14]. In addition, the route of PAF synthesis described in several biological
PAF receptor antagonist SKF 96148 prevented these systems is catalyzed by a choline phosphotransferase that
effects of PAF infusion [14]. However, Handa et al have uses cytidine 59-diphosphate (CDP) choline and 1-O-alkyl-
reported that the infusion of PAF as a bolus (5 to 10 2-acetyl-sn glycerol (alkylacetylglycerol) as substrate [22].
ng · kg21) into the renal artery of rats produces a dose- Pirotzky et al observed that perfused rat kidneys re-
dependent increase in RBF, which was abolished by the lease PAF after adding the calcium ionophore A23187 to
PAF receptor antagonist L-659,989 [15]. In isolated per- the perfusion medium or after perfusion with an alkaline
fused rat kidneys, PAF, at concentrations between 1028 medium [23]. It has been suggested that the release of
PAF by the isolated kidney in response to the calciumand 1025 m, causes a dose-dependent decrease in RVR
ionophore A23187 is not linked to the production of[16], but a decrease in GFR [17].
renal prostaglandins [24]. Renomedullary kidney cellsA possible explanation for these apparent discrepanc-
also produce significant amounts of PAF after incubationies can be found in the work of Juncos et al [18]. These
with ionophore A23187 [25]. The glomeruli are also ableauthors studied the direct effect of PAF on isolated mi-
to synthesize and release considerable amounts of PAFcroperfused rabbit glomerular afferent arterioles. At na-
[26]. Although endothelial cells are able to produce sig-nomolar concentrations, PAF caused a dose-dependent
nificant amounts of PAF, the major source of glomerularconstriction of afferent arterioles. This constriction was
PAF seems to be the mesangium, as cultured mesangialblunted by cyclooxygenase inhibition but was enhanced
cells synthesize high amounts of PAF, both in basal con-by nitric oxide (NO) inhibition. When arterioles were
ditions and after activation [26]. Moreover, incubation
preconstricted with norepinephrine, picomolar concen- of mesangial cells with PAF induces de novo PAF synthe-
trations of PAF (lower than those causing vasoconstric- sis by these cells. No PAF synthesis by cultured glomeru-
tion) produced a dose-dependent vasodilation that was lar epithelial cells or by tubular cells has been observed,
unaffected by cyclooxygenase inhibition but was abol- and their inability to synthesize PAF seems to be due
ished by NO synthesis inhibition. This study strongly to the absence of acetyl-transferase activity in these cells
suggests that PAF exerts a receptor-mediated biphasic [27]. The mechanisms of increased PAF synthesis and
effect on afferent arterioles, dilating them (if previously release by mesangial cells in response to ischemia/anoxia
constricted) at low concentrations and constricting them or toxic substances are represented in Figure 2.
at higher concentrations. This study also suggests that
the vasoconstrictor effect is mediated, at least in part,
PLATELET-ACTIVATING FACTOR AND
by cyclooxygenase products, whereas vasodilator activity EXPERIMENTAL MODELS OF ACUTE
would be mediated by NO. RENAL FAILURE
Considering both the effect of PAF on renal functionPlatelet-activating factor production by the kidney
and the ability of several kidney structures to synthesize
The renal origin of PAF was suggested by Caramelo and release PAF in response to several stimuli, PAF seems
et al, who reported the presence of PAF in blood from to be a good candidate as a mediator of the hemodynamic
normal human and experimental animals, but not in blood and other renal alterations associated with ARF. The
from anephric patients or bilaterally nephrectomized an- development of reliable methods to measure PAF levels
imals [19]. In addition, Sanchez-Crespo et al found a in biological fluids [28] as well as the development of
PAF-like substance in the urine of normal subjects [20]. molecules that specifically block the binding of PAF to
All of the biochemical machinery necessary for the syn- its receptors [29, 30] has allowed researchers to evaluate
thesis and degradation of PAF are present in the kidney. the importance of locally generated PAF in the physio-
pathology of renal failure. Table 1 reviews the studiesThe main metabolic pathways for PAF synthesis are
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Fig. 1. Main enzymatic pathways responsible
for the synthesis of PAF and its precursors.
The numbers designate the following enzymes:
1, alkyl-DHAP synthase; 2, NADPH:alkyl-
DHAP oxidoreductase; 3, AcetylCoA:Alkyl-
lysoglycerol-P acetyltransferase; 4, acyl-CoA:
alkylglycero-P acyltransferase; 5, Alkylacetyl-
glycerophosphate phosphohydrolase; 6, Alkyl-
acylglycerophosphate phosphohydrolase; 7,
CDPcholine: alkylacylglycerol cholinephospho-
transferase; 8, DTT-insensitive: CDPcholine:
alkylacetylglycerol cholinephosphotransferase;
9, phospholipase A2; 10, CoA-independent
transacylase; and 11, acetylCoA:lysoPAF ace-
tyl transferase.
in which treatment with PAF antagonists has improved Filep et al have also shown that after intestinal ischemia
induced by upper mesenteric artery ligation, PAF con-renal function in several experimental models of ARF.
centration increases in the upper mesenteric vein [34].
Hemodynamically mediated renal failure In another experimental model of renal failure with
a major hemodynamic component, that is, that inducedLopez-Farre´ et al have reported that glomeruli iso-
lated from rats undergoing a one-hour period of ischemia by intramuscular injection of glycerol, elevated glomeru-
lar synthesis of PAF was also observed by Lo´pez-Farre´show increased PAF synthesis; this is supported by the
increased [3H]acetate incorporation to PAF [31] and by et al [35].
The role of PAF in the genesis of ARF is furtherthe increased release of bioassayable PAF-like material
[32]. Moreover, these animals had a higher PAF concen- supported by the effects of PAF antagonists on the
course of renal function in experimental models of thetration in the renal venous effluent [32]. The elevation
in blood PAF levels has also been shown in the ischemia disease. Thus, it has been reported that treatment with
several PAF antagonists (Table 1) significantly protectsof other organs. Montrucchio et al have reported an
increased PAF release during the first minutes of reper- against the ARF induced by renal ischemia [31, 36–39].
Kelly et al have suggested that the role of PAF in renalfusion after cardiac ischemia in the rabbit [33], while
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Table 1. PAF-antagonist treatment in experimental models
of acute renal failure
Model PAF-antagonist Reference
Ischemia BA-52021 [31, 36, 37]
Ischemia Alprazolam [31]
Ischemia TVC 309 [38]
Ischemia WEB 2086 [39]
Ischemia Ro 24-476 [40]
Glycerol BN-52021 [35, 43]
Glycerol Alprazolam [35]
Cyclosporine A BN-52021 [52]
Cyclosporine A BN-52063 [51, 53]
Gentamicin BN-52063 [58]
Gentamicin BN-52021 [59, 60]
Cisplatin BN-52063 [58]
Cisplatin BN-52021 [59, 60]
Kidney graft rejection RP-48740 [65]
Kidney graft rejection WEB-2086 [66, 67]
Kidney graft rejection SRI 63-441 [68]
Pancreatitis BN-52021 [72]
Endotoxemia L 653-150 [76]
Endotoxemia L 652-731 [76]
Endotoxemia BN-52021 [77]
Endotoxemia SRI 63-675 [77]
Endotoxemia BN-50739 [78]
In all of these studies, treatment with the PAF-antagonist increased the glo-
merular filtration rate and/or renal blood flow.
Fig. 2. Mechanisms of increased platelet activating factor (PAF) syn-
thesis in response to ischemia/anoxia or nephrotoxic substances in mes-
angial cells. Ischemia and toxins impair oxidative metabolism, and in
The effects of PAF antagonist in ameliorating renalconsequence, cell adenosine 59-triphosphate (ATP) decreases, thus de-
creasing the ability of the cells to re-uptake calcium into the sarcoplasmic failure have been also observed in ARF induced by intra-
reticulum or pump calcium out of the cells. The increase in cytosolic muscular glycerol injection [35, 43].
calcium activates calcium-dependent membrane phospholipase A2, which It has been also demonstrated that endothelin playsacting on membrane 1-O-alkyl-2-acyl-glycerophosphocholine gives Lyso-
PAF and a free fatty acid, frequently arachidonic acid, which in turn, a major role in GFR reduction after renal ischemia [44, 45]
is transformed into eicosanoids by cyclooxygenases. Lyso-PAF is trans- and that this is mediated, at least in part, by PAF. Experi-
formed in PAF by an acyl-transferase. PAF comes out of the cell and,
ments performed at our own laboratory have shown thatacting on specific receptors, increases cytosolic free calcium. No evidence
of the activation of the CDP-choline phosphotransferase pathway of endothelin induces the synthesis and release of PAF
PAF synthesis in ischemia/anoxia or cell toxicity is currently available. from isolated glomeruli [46]. Other vasoconstrictor pep-
tides such as angiotensin II and vasopressin, also involved
in ARF, appear to stimulate PAF synthesis by endothe-
lial cells [47]. PAF antagonists BN-52021 and WEB-2170injury after ischemia would be mediated by its effect on
are able to partially block the contractile effects of endo-leukocyte–endothelial interactions [40]. This notion is
thelin in cultured mesangial cells [46]. Data obtained atalso supported by the data of Riera et al, who showed
our laboratory also show that endothelin-1 increases thethat in rat kidneys subjected to four hours of cold ische-
release of a substance that shares chemical and biologicalmia and subsequent reperfusion with Krebs-Henseleit
properties with PAF from isolated rat glomeruli. More-solution containing 4.5% albumin with and without hu-
over, endothelin-1 enhances the incorporation of acetateman polymorphonuclear neutrophils, the presence of
into PAF both in isolated glomeruli [46] and culturedneutrophils in the perfusion solution produces a signifi-
mesangial cells [48]. Both effects have a similar EC50,cant worsening of renal function [41]. In addition, the
suggesting that endothelin-1 induces PAF synthesiskidneys reperfused with neutrophils produced more PAF
through the acetyl-transferase pathway [42]. Further sup-than those reperfused without neutrophils. Addition of
port for the involvement of endothelin and PAF in thethe PAF antagonist BN-52021 to the reperfusion fluid
genesis or maintenance of ischemic ARF is provided byincreased renal function in a dose-dependent manner
studies showing that treatment with anti–ET-1 antibod-in comparison with kidneys perfused without BN-52021
ies clearly improves the course of ischemic ARF and[41]. These results suggest that neutrophils contribute to
significantly decreases the glomerular release of PAF inthe renal injury induced by ischemia reperfusion through
rats after one hour of renal ischemia [45].a mechanism that seems to be mediated by PAF release.
Another family of substances related to ischemia-reper-In addition, another PAF antagonist, TCV-309, reduces
fusion events is reactive oxygen species (ROS) [49]. Stud-graft polymorphonuclear cell infiltration and enhances
renal function in kidneys with long, warm ischemia [42]. ies from our laboratory have shown that hydrogen perox-
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ide induces mesangial cell contraction and myosin light- inhibited by incubation with the PAF antagonists BN-
52021 and alprazolam. Furthermore, we have demon-chain phosphorylation, both effects being abolished by
the PAF-antagonist BN-52021 [50]. Hydrogen peroxide strated that mesangial cells incubated with gentamicin
produce higher amounts of PAF and eicosanoids thanalso stimulates PAF synthesis by mesangial cells [50].
These findings suggest that the possible effect of in- control cells through a mechanism mediated by the acti-
vation of Ca-dependent phospholipase A2 [62].creased ROS production on mesangial cell contraction,
a major determinant of Kf reduction and hence GFR Cisplatin nephrotoxicity. Cisplatin is a valuable agent
in oncologic therapy but has many adverse side-effects,decrease, may be mediated by ROS-stimulated synthesis
and release of PAF by the glomerular mesangium. nephrotoxicity being the most common and important
one. Cisplatin treatment in rats induces a nonoliguricAll of these data suggest that local PAF generation
in response to ischemia or secondary to other vasoactive ARF, with a marked decrease in GFR and RBF [63].
Treatment with the PAF antagonists BN-52063 or BN-mediators plays a major role in the renal and intraglo-
merular hemodynamic alterations seen in experimental 25021 completely prevented the cisplatin-induced ARF,
as all the parameters of renal function returned to normalmodels of ischemic ARF.
values [58, 64].
Nephrotoxic acute renal failure Taken together, these results suggest that a major role
exists for local PAF release in the nephrotoxicity inducedCyclosporine A nephrotoxicity. Immunosuppressive
by a variety of drugs, such as aminoglycosides, cyclospo-therapy with cyclosporine is often associated with the
rine, and cisplatin.appearance of renal failure. A role for PAF as being
responsible for renal function derangement in animals
Hyperacute xenogenic rejection of renal transplantstreated with cyclosporine has been inferred from differ-
ent types of experiments. In this sense, pretreatment The pathogenesis of hyperacute transplantation reac-
tions includes the activation of a cascade of nonspecificwith the PAF antagonists BN-52021 or BN-52063 pre-
vented the decrease in GFR induced by cyclosporine inflammatory reactions that precipitate the destruction
of target organs. In the case of the kidney, a sharp de-administration in rats [51–53]. Several mechanisms can
be invoked to explain the PAF-antagonist–induced ame- crease in GFR and the subsequent ARF is an early mani-
festation of hyperacute rejection. PAF seems to representlioration of renal function after cyclosporine-induced re-
nal failure. First, the PAF antagonist L-659,989 signifi- an important component of these inflammatory cascades,
and its role in mediating hyperacute kidney rejectioncantly reduces cyclosporine-induced afferent arteriole
constriction [54]. The PAF antagonist BN-50726 reduces comes from studies using PAF antagonists. Thus, in
Lewis rats that are receiving allogenic kidney transplantsrenal membrane peroxidation induced by cyclosporine
treatment in rats [55]. In addition, cyclosporine induces from Brown Norway rats, the PAF antagonist RP 48740
delays accelerated kidney rejection [65]. Similar resultsmarked cell damage and reduced oxidative metabolism
in LLC-PK1 cells, a tubular cell line [56]. Two PAF antag- were observed with the PAF antagonist WEB 2086 [66].
This PAF antagonist also markedly reduces eicosanoidsonists, PMS 536 and PMS 549 [56], prevent these effects.
Moreover, the contractile effect of cyclosporine on mes- and tumor necrosis factor-a (TNF-a) release after renal
xenografting in pigs [67]. Furthermore, the PAF antago-angial cells can be prevented by coincubation with PAF
antagonists [57], and cyclosporine induces PAF synthesis nist SRI 63-441 prevents the acute rejection of cat-to-
rabbit kidney xenografts and prolongs graft survival [68].and release by cultured rat mesangial cells [57].
Gentamicin nephrotoxicity. In other model of nephro- SRI 63-441 also inhibits hyperacute rejection of rat car-
diac allografts by presensitized rat recipients, as well astoxicity with a major tubular component, such as genta-
micin-induced renal failure, PAF synthesis and release by guinea pig-to-rat and mouse-to-rat cardiac xenografts.
In addition, a dramatic increase has been observed inthe kidney also seem to have an important pathogenic role.
Thus, Pavao dos Santos et al and Rodriguez-Barbero the production of a PAF-like substance by renal allograft
tissue undergoing untreated hyperacute rejection [69].et al have demonstrated that both tubular damage and
the reduction in GFR induced by gentamicin treatment In a pioneer clinical, double-blind, randomized study
[70], kidney donors were treated with BN-52021 (240in rats can be partially prevented by treatment with the
PAF antagonists BN-52021 and BN-52063 [58, 59]. Im- mg, i.v.) or placebo just before kidney harvesting. The
kidneys were perfused and stored at 48C, adding BN-munoreactive PAF production is higher in glomeruli
from rats treated with gentamicin than in those from 52021 (0.08 mg/ml) or placebo to the preservation fluid.
Recipients also received BN-52021 or placebo over thecontrol rats [60].
We have observed that gentamicin has a direct effect first four days after transplantation. After a minimum
follow-up of three months, the occurrence of post-trans-on mesangial cells, inducing cell contraction and an in-
crease in cytosolic-free calcium [61]. Both effects can be plant renal failure was significantly lower in the BN-
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52021 group (0 of 14) than in the placebo group (5 of MECHANISMS MEDIATING PLATELET-
ACTIVATING FACTOR–INDUCED15) [70].
RENAL FAILUREAll of these data suggest that PAF synthesis and action
in the transplanted kidney suffering hyperacute rejection The mechanisms responsible for PAF-induced falls in
play an important role in mediating the immunologic GFR are not well known, but all of the available evidence
and hemodynamic events associated with renal failure suggests that one is dealing with a multifactorial phenom-
secondary to graft rejection. enon. At least three mechanisms are involved: a direct
effect of PAF on RBF, an effect of PAF on Kf, and the
stimulation by PAF of the release of other vasoactiveRENAL FAILURE ASSOCIATED WITH
mediators. These mechanisms are depicted in Figure 3.EXTRARENAL DISEASES
Acute pancreatitis Platelet-activating factor–induced reduction in renal
blood flowCourses of acute pancreatitis have profound hemody-
namic disturbances and renal failure. Some reports have Platelet-activating factor–induced decreases in GFR
suggested that PAF can also play a role as a mediator could be based on the decrease in RBF [12, 13]. An
of the pathophysiological alterations observed in certain explanation for this decrease is that PAF raises RVR
experimental models of pancreatitis. PAF is involved in due to a direct contractile effect on vascular smooth
the development of acute pancreatitis induced by immu- muscle [9, 12, 83]. In fact, Juncos et al have demonstrated
nocomplex injection [71]. Treatment with PAF antago- a direct effect of PAF on contracting, isolated, microper-
nists ameliorates the hemodynamic alterations associ- fused afferent arterioles [18]. Moreover, afferent arteri-
ated with acute pancreatitis induced by retrograde ole contraction also decreases intracapillary hydrostatic
injection of sodium deoxycholate [72]. Specifically, treat- pressure, which is the major force responsible for glomer-
ment with BN-52021 prevented the sharp decrease in ular ultrafiltration. Another mechanism responsible for
RBF associated with this model of acute pancreatitis [72]. PAF-induced decreases in GFR is that PAF causes a
In addition, PAF also seems to be involved in chronic decrease in plasma volume, caused by plasma extravasa-
pancreatitis induced by bile duct ligation in the rat [73]. tion toward the interstitial compartment [84], with subse-
Moreover, PAF administration to rabbits induces pan- quent activation of the sympathetic nervous system.
creatitis [74], and long-term administration of PAF to However, the reduction in GFR induced by PAF infusion
rats reduces both pancreatic regeneration and amylase can be observed in the absence of hypotension and hem-
release [73]. An increase in pancreatic PAF levels has oconcentration [11–14]. Ins addition, PAF can also act
also been reported in animals with cerulein-induced pan- as a coinflammatory agent and increase microvascular
creatitis [75]. thrombosis and vascular obstruction, thus reducing RBF
and GFR [4, 5].
Endotoxemic acute renal failure
Platelet-activating factor–induced decrease in theEndotoxemia and endotoxemic shock are associated
ultrafiltration coefficientwith a sharp decrease in GFR and renal failure. Wang
and Dunn have demonstrated that treatment with PAF A decreased Kf has been suggested to play a role in
antagonists such as L 653-150 and L 652-731 significantly several models of ARF. It should be noted that PAF
prevents the decrease in GFR and RBF induced by the infusion in rats induces a decrease in GFR, RBF, and Kf
injection of endotoxin in rats [76]. Tolins et al have also [13]. The ARF induced by cyclosporine [51], cisplatin [58],
observed that the PAF-antagonists BN-52021 and SRI or gentamicin [58, 85, 86] is associated with marked de-
63-675 prevent the fall in GFR, RBF, and urinary flow crease in Kf as measured by micropuncture techniques.
associated with endotoxin infusion in the rat [77]. Similar In these models, treatment with the PAF antagonists
observations were reported by Rabinovici et al using BN-52021 or BN-52063 reversed the drug-induced de-
BN-50739 [78]. Dobrowsky et al and Mozes et al have crease in Kf [51, 58].
demonstrated increased blood levels of PAF after endo- In isolated rat glomeruli, Sharma et al have recently
toxin injection in pigs [79, 80], whereas Morell et al described that PAF reduces glomerular capillary hydraulic
have reported a dose- and time-dependent stimulation of conductivity (a major component of Kf) and albumin per-
glomerular PAF production by lipopolysaccharide [81]. meability [87]. Some authors have suggested that mesan-
Chang et al have reported increased renal PAF levels gial cell contraction and the subsequent glomerular con-
after endotoxin administration [82]. traction reduce the glomerular filtration surface and Kf
All these data suggest that lipopolysaccharide-stimu- [88]. PAF is able to contract both isolated glomeruli [89]
lated renal PAF production plays a major role in reduc- and cultured mesangial cells [90, 91]. It should be noted
that substances that induce a decrease in Kf, such asing GFR during endotoxemia.
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Fig. 3. Mechanisms of platelet activating fac-
tor (PAF)-induced decrease in glomerular fil-
tration rate (GFR). The numbers in parenthe-
ses are the citations reporting these effects.
Plus and minus signs represent increase and
decrease, respectively.
cyclosporine or gentamicin, also induce mesangial cell con- Histamine. Another vasoactive substance released by
the perfused kidney in response to PAF is histamine [94].traction. Incubation with the PAF antagonists BN-52021
or alprazolam [57, 61] can prevent this contraction. When isolated rat kidneys are stimulated with calcium
ionophore A23187, kidneys release both PAF and hista-
Release of other vasoactive mediators mine [23]. Furthermore, guinea pig kidneys also release
Cyclooxygenase products. In isolated perfused rabbit PAF and histamine after an antigenic shock induced by
kidney [92], rat kidney [13, 14], and isolated rat glomeruli ovalbumin administration [95]. The PAF-receptor antag-
[93], PAF administration increases the production of onist BN-52021 is able to antagonize histamine release
thromboxane B2 (TxB2), the stable metabolite of throm- by isolated kidneys subjected to antigenic shock in a
boxane A2 (TxA2), a potent vasoconstrictor. Also, in concentration-dependent way [95]. Histamine, infused
cultured rat and human mesangial cells, PAF induces a directly into the renal artery, causes decreases in RVR
dose-dependent stimulation of TxB2 and prostaglandin and increases in RBF, without significant changes in
E2 (PGE2) release that can be specifically blocked by the mean arterial blood pressure and GFR, thus reducing
PAF antagonists Kadsurenone or BN-52021 (abstract; glomerular filtration coefficient [96, 97]. Glomeruli are
Stork et al, Kidney Int 27:267A, 1985). In rats, the de- the major sites of histamine synthesis in the kidney [97],
crease in GFR and RBF observed in response to intrare- and histamine induces a dose-dependent contraction of
nal PAF infusion was abolished in the presence of the isolated rat glomeruli and cultured rat mesangial cells
cyclooxygenase inhibitors indomethacin and ibuprofen [98]. Thus, if glomerular cells in response to PAF release
[13, 14]. Moreover, when administered concomitantly histamine and histamine induces mesangial cell contrac-
with a TxA2 receptor antagonist, PAF led to significant tion, histamine could mediate at least a part of the glo-
increases in GFR and RBF [13]. PAF-induced mesangial merular actions of PAF.
cell contraction increases if prostaglandin synthesis is
blocked and is partially reversed by the addition of PGE2
MECHANISMS UNDERLYING PLATELET-(abstract; Stork et al, ibid). The PAF-induced increases
ACTIVATING FACTOR–INDUCEDin GFR and RBF when PAF is administered simultane-
CELL CONTRACTIONously with a TxA2 receptor antagonists can be explained
As mentioned earlier in this article, the mechanismsby the vasodilator effect of both PGE2 and NO released
underlying PAF-induced reductions in GFR and RBFin response to PAF.
These results suggest that glomerular eicosanoid pro- are based on the contractile effect of PAF on both mes-
angial and vascular smooth muscle cells. The cellularduction in response to PAF could regulate PAF-induced
changes in renal function. mechanisms responsible for cell contraction are appar-
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ently similar in both vascular smooth muscle cells and those reported for other vasoconstrictor substances such
as angiotensin II, endothelin, arginine vasopressin (AVP),in mesangial cells. First, the effect of PAF on cell contrac-
tion is mediated by the specific binding of this molecule or serotonin.
to its receptors, as contraction is completely prevented
by preincubation with either of the PAF-acether receptor
CONCLUSION
antagonists L652,731 or BN-52021 [86]. These PAF re-
This review provides reasonable experimental evi-ceptors have been studied in depth [99] and have been
dence to support the role of PAF as a mediator of reduc-cloned by functional expression by Honda et al [100].
tions in GFR in several models of experimental ARF ofHydropathy analysis of these receptors revealed seven
ischemic or toxic origin. The involvement of PAF inputative transmembrane segments that are now recog-
renal failure associated with glomerular immune diseasenized as a characteristic feature of G-protein–coupled
has been also demonstrated elsewhere, although thisreceptors. There is a total of 12 tyrosine residues that
topic is beyond the scope of this review. None of theare candidate substrates for tyrosine kinases: six in the
studies performed in experimental animals can be ex-cytoplasmic tail and two in each of the cytoplasmic loops
trapolated directly to clinical ARF, and further research[99]. Several asparagine residues are present at the exter-
into this topic is undoubtedly needed. However, our cur-nal surface of the receptor and can serve as sites for
rent understanding of the mechanisms controlling theattachment of glycosylated residues.
release and actions of PAF, although incomplete, shouldIt has been reported that the interaction between PAF
finally provide the scientific basis for the preventive andand its receptor activates several transmembrane signaling
therapeutical use of PAF antagonists and other drugsmechanisms. For example, PAF activates phospholipase C,
able to modify PAF synthesis in human ARF.phospholipase A2, and phospholipase D, protein kinase C,
and tyrosine kinase [99]. G proteins have been implicated
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